Markets:

Overview

News

Currencies

International

Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

444.83 +6.10 (+1.39%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Top 3 Health Care Stocks That May Dip This Month ↗

November 25, 2024

Via Benzinga

Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst ↗

November 25, 2024

Via The Motley Fool

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move ↗

November 23, 2024

Via The Motley Fool

MDGL: A Promising Play In The Weight Loss Drug Space ↗

November 22, 2024

The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now...

Via Talk Markets

Topics Stocks / Equities

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More ↗

November 10, 2024

There's a bright future ahead for this company.

Via The Motley Fool

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗

November 03, 2024

Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).

Via Benzinga

Earnings Preview For Madrigal Pharmaceuticals ↗

October 30, 2024

Via Benzinga

Is Madrigal Pharmaceuticals Stock a Buy? ↗

May 21, 2024

It's not the most prominent biotech, but it has an important claim to fame.

Via The Motley Fool

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗

November 01, 2024

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

Is Madrigal Pharmaceuticals Stock a Buy? ↗

August 17, 2024

The biotech could be worth a lot more in 10 years.

Via The Motley Fool

This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock ↗

August 14, 2024

One player's minor pain is another's moderate gain.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 12, 2024

Via Benzinga

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' ↗

August 07, 2024

Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations.

Via Investor's Business Daily

Topics Earnings

Is It Too Late to Buy Madrigal Pharmaceuticals Stock? ↗

August 05, 2024

Will being the first to its market ensure that its future is bright?

Via The Motley Fool

7 Biotech Stocks to Keep on Your Clinical Radar ↗

July 23, 2024

Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.

Via InvestorPlace

Is Madrigal Pharmaceuticals a Millionaire Maker? ↗

June 30, 2024

Its revenue ramp-up is just starting, and its market looks lucrative.

Via The Motley Fool

Is Madrigal Pharmaceuticals Stock a Buy? ↗

June 28, 2024

The company could become a prominent player in the biotech industry, but that might take a while.

Via The Motley Fool

The Best Biotech Stock to Invest $1,000 in Right Now ↗

June 18, 2024

This stock may not be a slam dunk, but it's looking very promising.

Via The Motley Fool

Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender ↗

June 17, 2024

The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.

Via Investor's Business Daily

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. ↗

June 16, 2024

Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade.

Via The Motley Fool

Where Will Madrigal Pharmaceuticals Be in 3 Years? ↗

June 15, 2024

The coast is clear for it to grow, for now.

Via The Motley Fool

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗

June 12, 2024

On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 11, 2024

Via Benzinga

Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗

June 10, 2024

Success isn't guaranteed, but both companies could become big winners.

Via The Motley Fool

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? ↗

June 05, 2024

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....

Via Benzinga

Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH ↗

June 05, 2024

Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease.

Via Investor's Business Daily

DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 05, 2024

Via Benzinga

Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug ↗

June 04, 2024

Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease.

Via Investor's Business Daily

The Week Ahead: What's Next ↗

June 02, 2024

The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.